SUMMARY Following reports of the successful management of cutaneous malignant melanoma with azelaic acid both locally and systemically a trial was undertaken to assess its value in the treatment of similar lesions involving the eye and its adnexa. Systemically administered azelaic acid failed to influence the melanomata in any of the 4 patients included in the study. A plea is made for the reporting even of such disappointing results in the present uncertain climate.
The recent suggestion that enucleation of eyes harbouring malignant melanoma could precipitate dissemination of the tumour' has provoked considerable debate as to the best management of such eyes. 2 While it is recognised that ocular melanomata grow slowly in comparison with their cutaneous counterparts,2 nevertheless two independent followup studies on patients refusing enucleation have shown 100% of deaths from metastases.4" To many ophthalmologists, therefore, simply observing such lesions would be an unacceptable approach.
In this climate of uncertainty reports of a chemotherapeutic agent cytotoxic to cutaneous melanomata6 stimulated us to investigate its efficacity in ocular and adnexal malignant melanoma. We report our results in treating 4 patients with azelaic acid.
Patients and methods
All 4 patients were attending the Medical Ophthalmology Clinic at the Birmingham and Midland Eye Hospital and had either refused surgical intervention or, after detailed explanation, requested a trial with this agent prior to surgery. The diagnosis ofmalignant melanoma was agreed by the referring ophthalmologist and both authors prior to entry into the study. Detailed informed consent and a full medical history, with specific attention being paid to gastrointestinal, genitourinary, and dermatological symptoms, were obtained. Each patient was examined by the authors to exclude clinical evidence of metastases or any unrelated systemic disorder, and a battery of investigations were performed including: haemoglobin and full blood count; urea, creatinine, and electrolyte levels; enzyme studies including SGOT, SGPT, creatinine kinase, and alkaline phosphatase; lactic dehydrogenase levels; and plasma protein analysis. The patients were then started on a regimen of 12 g of azelaic acid per day, in 4 (Fig. 2) . Lost to follow-up for 6 months. On 13 December 1979 the lesion had increased greatly in size. Exenteration refused: Reviewed until 11 September 1980, when course of azelaic acid started. After 1 month her creatinine kinase was elevated and she became hypokalaemic. During this month the lesion had increased in size, and she was persuaded to accept left enucleation with a wide conjunctival excision with grafting.
Histology. Highly anaplastic malignant melanoma of limbus arising from an area of intraepithelial melanosis. Actively mitotic but with no invasion of globe. Moderate to heavy pigmentation.
Review on 14 November 1981: well, with no evidence of recurrence. (Fig. 4) There are a number of possible explanations for the lack of effectivity in these patients. Intraocular penetration is unknown, and a failure to penetrate the blood-aqueous barrier might explain failure in cases 1 and 4. This would not, however, have prevented access to the tumours in cases 2 and 3. It seems unlikely that there are major differences in the size of these tumours as compared to the cutaneous lesions treated successfully,6 and it is also unlikely that melanomata of both the globe and its adnexa show major histological differences from cutaneous lesions.
It may be relevant that the azelaic acid used in this series was produced as a laboratory standard powder and was mnuch modified for patient consumption. Its purity and the reliability of its chemical characteristics were first checked, and it was then converted into a sodium salt to improve its solubility. Any of these manoeuvres may have removed or modified some associated factor which in previous work had proved beneficial.
Finally, while the agent was well tolerated by 3 patients, we suspected systemic toxicity in patient 2, who developed a profound hypokalaemia (2-1 mmol/l) while on treatment.
CONCLUSION
Given the current status of intraocular melanoma management, we feel exploration ofpotentially useful chemotherapeutic agents is justifiable. Care must be taken to obtain detailed consent, and it is important that even negative results be reported to avoid wasteful duplication of cfinical investigative efforts. We have not found azelaic acid to be a useful chemotherapeutic agent in the management of ocular and adnexal malignant melanoma.
